Live
FierceBiotechAutobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2Endpoints NewsHikma to funnel $267M to Ohio; Cingulate gets CRL for ADHD drugCellPaleogenomes reveal the evolutionary relationship between modern and cave lionsEndpoints NewsLilly, Boehringer retrench in Germany on proposed health spending cutsEndpoints NewsSupreme Court sides with Hikma in 'skinny label' caseFierceBiotechAs China biotech crackdown calls reverberate in Washington, the pushback gets louder, tooEndpoints NewsNovo Holdings backs European fund; Alnylam sends second obesity drug into clinicBioPharma DiveAlnylam, Inceptive ink AI deal potentially worth $2BFierceBiotechParabilis preps $413M IPO to fuel desmoid tumor drug into phase 3Thermo FisherThermo Fisher Introduces M Series Centrifuges - Contract PharmaLonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila TimesLonza NewsStipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila Times
Illumina 27 févr. 2026

Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics - PR Newswire APAC - PR Newswire Asia

Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics - PR Newswire APAC - PR Newswire Asia

Contenu indisponible. Consultez la source originale.